首页 | 官方网站   微博 | 高级检索  
相似文献
 共查询到17条相似文献,搜索用时 203 毫秒
1.
鲁静  马萍 《国际眼科杂志》2022,22(2):314-317
目的:研究跨上皮快速角膜胶原交联术(CXL)治疗进展期圆锥角膜的临床效果和安全性。方法:前瞻性自身前后对照研究。收集自2016-08/2019-11在我院进行跨上皮快速CXL的进展期圆锥角膜患者37例47眼,分析患者术前,术后1、3、6、12mo的裸眼视力(UCVA)和最佳矫正视力(BCVA)、屈光状态、角膜透明度、角膜前表面最大K值(Kmax)、角膜最薄点厚度、角膜内皮细胞计数、眼压。结果:术后1、3、6、12mo患者UCVA较术前提高,但总体比较无差异(F=1.372,P=0.261)。患者术后1、3、6、12mo的BCVA均较术前提高,总体比较有差异(F=3.308,P=0.019),进一步比较发现术后3、6、12mo的BCVA与术前比较有差异(P=0.04、0.01、0.007)。患者术后1、3、6、12mo的球镜度数、柱镜度数、Kmax、角膜最薄点厚度与术前总体比较无差异(F=0.293、1.378、2.448、1.970,P=0.881、0.258、0.061、0.116)。术后1mo患者角膜内皮细胞计数与术前比较无差异(t=1.156,P=0.25)。患者术后各时间点眼压与术前比较无差异(F=1.221,P=0.321)。术后7眼出现角膜Haze(1级~2级),术后3~6mo有5眼Haze消退,角膜恢复透明,1眼遗留角膜云翳,1眼角膜中央基质线状混浊,但均未对视力造成影响。结论:跨上皮快速CXL可以显著提高圆锥角膜患者BCVA,稳定患者屈光状态、角膜形态和厚度,阻止或延缓圆锥角膜进展,使患者获得更好的视功能,同时手术时间短,术后并发症少,具有较好的安全性。  相似文献   

2.
目的:评估核黄素/紫外线A胶原角膜交联术(CXL)治疗薄角膜圆锥角膜患者术后的长期疗效。方法: 前瞻性研究。收集2015年1-7月因圆锥角膜于山东大学附属省立医院眼科行CXL治疗的患者19例(32 眼),其中男12例(21眼),女7例(11眼)。以角膜基质厚度400 µm为分界线,将圆锥角膜患者分为薄 角膜组和厚角膜组。薄角膜组使用低渗性核黄素溶液进行角膜交联术治疗,厚角膜组使用等渗核 黄素溶液进行CXL治疗,术后随访3年,观察角膜最大K(Kmax)值、裸眼视力(UCVA)、最佳矫正 视力(BCVA)、最薄处角膜厚度(TCT)、眼压及角膜内皮细胞计数(ECD)等参数变化。采用重复测 量方差分析、t检验、Wilcoxon符号秩和检验、Mann-Whitney U检验进行数据处理。结果:薄、厚角 膜组术后Kmax值随时间延长均持续降低(F=24.364,P<0.001;F=10.427,P=0.001);薄角膜组术前, 术后1、2、3年Kmax值分别为(60.51±6.11)D、(57.43±6.82)D、(56.13±6.85)D、(54.97±6.66)D, 术后各时间点与术前相比差异均有统计学意义(t=3.670,P=0.002;t=4.637,P<0.001;t=5.816,P< 0.001);厚角膜组术前,术后1、2、3年Kmax值分别为(54.56±6.27)D、(53.25±6.42)D、(52.32± 6.47)D、(51.58±6.70)D,术后各时间点与术前相比差异均有统计学意义(t=2.266,P=0.040; t=3.302,P=0.005;t=3.769,P=0.002);术前薄角膜组Kmax值高于厚角膜组(t=2.714,P=0.011),术 后1、2、3年2组间Kmax值差异无统计学意义。术后3年,薄角膜组UCVA、BCVA、TCT与术前 相比差异有统计学意义(Z=-2.716,P=0.007;Z=-3.063,P=0.002;t=4.468,P<0.001),厚角膜组 UCVA、BCVA、TCT与术前相比差异有统计学意义(t=3.572,P=0.003;Z=-2.956,P=0.003;Z= -3.410,P=0.001)。2组眼压、ECD与术前相比差异均无统计学意义。薄、厚角膜组术前组间及术后 3年组间UCVA、BCVA、眼压、ECD比较差异均无统计学意义;术前、术后3年组间TCT差异有统计 学意义(Z=-4.816,P=0.001;Z=-4.024,P<0.001)。结论:CXL可以安全有效地控制薄角膜圆锥角膜 患者病情进展,提高视力。  相似文献   

3.
背景 圆锥角膜是一种角膜进行性膨隆和变薄的疾病,常于青少年时期发病,伴随不同程度的视觉质量下降.角膜胶原交联术(CXL)是利用维生素B2和紫外线A(UVA)之间的光氧化反应来增加角膜硬度,延缓甚至阻止圆锥角膜膨隆的进展. 目的 评估保留上皮CXL治疗青少年圆锥角膜的安全性和有效性. 方法 纳入2010年2月至2013年3月于温州医科大学附属眼视光医院拟行保留上皮CXL的原发性圆锥角膜患者9例10眼,年龄13 ~ 17岁,平均(15±1)岁.术中使用质量分数0.1%丁卡因滴眼液作为促渗剂点眼,再使用质量分数0.5%核黄素液点眼至前房饱和状态,最后使用强度为3 mW/cm2的紫外线A照射30 min.术后7d、1个月、3个月、6个月及12个月测量远距裸眼视力(UDVA)、远距矫正视力(CDVA)、球镜度、柱镜度、等效球镜度(SE)、角膜前表面最大角膜曲率值(Kmax)、角膜前后表面高度值、角膜最薄点厚度.术后7d测量角膜内皮细胞密度(ECD).记录术后角膜上皮愈合时间. 结果 保留上皮CXL术后角膜上皮平均愈合时间为(1.4±0.8)d.术后12个月时,平均UDVA、CDVA分别从术前的1.02±0.16和0.34±0.20改善至0.77±0.18和0.25±0.15,平均球镜度和SE分别从(-7.15±3.00)D和(-9.26±3.23)D改善为(-5.28±2.05)D和(-7.05±2.08)D,平均Kmax从(64.1±11.9)D降低至(61.8±10.4)D,差异均有统计学意义(t=4.251、3.750、-2.515、-2.597、2.304,均P<0.05).术前与术后12个月平均柱镜度、角膜最薄点厚度比较差异均无统计学意义(t=-1.331、0.328,均P>0.05).术前与术后7 d ECD的比较差异无统计学意义(t=1.205,P>0.05).有2眼分别在术后3个月和术后6个月开始出现持续的角膜基质混浊. 结论 保留上皮CXL能够安全、有效地延缓或阻止青少年圆锥角膜的进展.  相似文献   

4.
目的联合准分子激光治疗性角膜切削术(PTK)、准分子激光屈光性角膜切削术(PRK)和核黄素诱导的长波紫外线角膜胶原交联术(CXL)对准分子激光原位角膜摩镶术(LASIK)术后角膜膨隆进行交联和屈光重建,评价该方法对LASIK术后角膜膨隆的临床疗效。方法前瞻性自身对照研究。选择早中期LAISK术后角膜膨隆患者14例(16眼),均采用PTK+PRK+CXL进行治疗,记录术前及术后1、3、6个月的裸眼视力(UCVA)、最佳矫正视力(BCVA)、角膜前表面最大曲率(Kmax)值、中央角膜厚度(CCT)、角膜内皮细胞密度(ECD)。应用Wilcoxon符号秩和检验行数据分析。结果16只患眼术前的LogMAR UCVA中位数为0.50,术后l、3、6个月的logMAR UCVA中位数分别为0.10、0.10和0.00,与术前相比均提高(P<0.01);术后1、3、6个月Kmax的中位数值分别为44.80、44.85、45.20 D,均较术前(47.15 D)降低(P<0.05);角膜厚度的中位数值在术后1、3、6个月分别为450、422、420 µm,与术前差异均有统计学意义(P<0.01)。而术后1、3、6个月的BCVA、ECD与术前差异均无统计学意义。结论PTK+PRK+CXL治疗LAISK术后角膜膨隆安全、有效,术后UCVA提高、Kmax降低。  相似文献   

5.
目的探讨保留上皮瓣的快速角膜胶原交联术(ACXL)治疗圆锥角膜的有效性及安全性。方法自身前后对照研究。对原发性圆锥角膜患者17例(17眼),术中先制作完整的上皮瓣,掀瓣后使用0.1%核黄素浸泡角膜基质10 min;再应用KXL系统进行紫外光照,光照强度30 mW/cm2,连续照射4 min,总能量7.2 J/cm2,最后复位上皮瓣。分别于术前,术后1、3个月,1年检查裸眼视力(UCVA)、显然验光、最佳戴镜矫正视力(BCVA)、haze分级、角膜曲率、圆锥角膜指数(KI)、角膜最薄点厚度及角膜内皮细胞密度等。采用一元重复测量方差分析、Dunnett-t检验和配对t检验对数据进行统计分析。结果术后1 d 3例患者疼痛评分2级,余均为1级。术后5 d所有术眼角膜上皮愈合。术后1年UCVA逐渐提高(F=3.245,P<0.05);等效球镜度逐渐降低(F=3.466,P<0.05);角膜平坦曲率(K1)和陡峭曲率(K2)先升后降(FK1=5.572,P<0.05;FK2=8.659,P<0.01);KI逐渐降低(F=3.660,P<0.05);角膜最薄点厚度变薄6%(F=20.501,P<0.01);BCVA、角膜内皮细胞密度及六角形细胞百分比变化差异无统计学意义。结论保留上皮瓣的ACXL控制圆锥角膜进展可能是安全有效的。  相似文献   

6.
目的 探讨去上皮快速角膜交联术紫外光脉冲输出模式(pl-快速CXL)和经上皮pl-快速CXL治疗进展期圆锥角膜患者的临床效果。方法 选取2018年1月至2019年6月在河北省眼科医院行pl-快速CXL治疗的进展期圆锥角膜患者16例31眼;根据术式将患眼分为两组,去上皮pl-快速CXL组7例13眼和经上皮pl-快速CXL组9例18眼。术前及术后3个月和6个月进行随访。记录患眼最佳矫正远视力、散光度、角膜前表面最大曲率、角膜前表面最小曲率、角膜最薄点厚度、角膜内皮细胞计数、交联线深度,对各指标进行统计学分析。结果 去上皮pl-快速CXL组和经上皮pl-快速CXL组患者术后3个月和术后6个月最佳矫正远视力、散光度、角膜前表面最大曲率、角膜前表面最小曲率、角膜内皮细胞计数与术前相比,差异均无统计学意义(均为P>0.05);术后3个月和术后6个月时两组角膜最薄点厚度均较术前变薄,差异均有统计学意义(均为P<0.05)。两组患者交联线深度术后3个月与术后6个月相比,差异均无统计学意义(均为P>0.05)。术后3个月和术后6个月时,去上皮pl-快速CXL组患者角膜交联线深度均较经上皮pl-快速CXL组更深,差异均有统计学意义(均为P<0.05)。对于相同时间点的其他参数而言,两组间差异均无统计学意义(均为P>0.05)。结论 无论是去上皮pl-快速CXL还是经上皮pl-快速CXL都安全可行,在术后6个月内均能够稳定圆锥角膜病情。  相似文献   

7.
目的通过准分子激光角膜上皮瓣下磨镶术(Epi-LASIK) 联合紫外线核黄素角膜交联术对早期圆锥角膜进行屈光重建和治疗,探讨该方法在早期圆锥角膜中的应用价值及临床意义。方法前瞻性研究。早期圆锥角膜患者18例(31眼),采用Epi-LASIK联合紫外线核黄素角膜交联术进行治疗,应用方差分析对术前及术后1、3、6个月的UCVA、BCVA、角膜地形图参数进行比较。结果31眼术前UCVA(logMAR)0.70±0.24, 术后1、3、6个月的UCVA分别为0.09±0.16、0.06±0.20、-0.06±0.03。术后1、3、6个月的UCVA均较术前提高(F=3.39,P<0.01)。术后1、3、6个月的BCVA较术前无明显提高。术前角膜K值为(46.65±2.91)D,术后1、3、6个月分别为(42.94±3.88)D、(41.72±4.38)D、(41.99±3.84)D,术后角膜较术前平坦(F=3.57,P<0.05)。结论Epi-LASIK 联合紫外线核黄素角膜交联术可以有效提高早期圆锥角膜患者的视力。  相似文献   

8.
目的 探讨角膜地形图引导的准分子激光上皮下角膜磨镶术(LASEK)治疗放射状角膜切开术(RK)后屈光不正的有效性及安全性。方法 回顾性系列病例研究。RK术后视功能下降行角膜地形图引导的LASEK联合丝裂霉素C(MMC)治疗的患者13例(16眼),分为远视组(11眼)和近视组(5眼)。对术前及术后1年等效球镜度(SE)及散光值进行配对t检验,对裸眼视力(UCVA)、最佳矫正视力(BCVA)和角膜地形图指数进行Wilcoxon秩和检验,并对手术并发症进行总结分析。结果 远视组手术前后UCVA中位数分别为0.22和0.09(logMAR)(Z=-1.732,P<0.05),术后9眼UCVA≤0.3,5眼UCVA≤0(logMAR);仅1眼BCVA下降1行,其余均等于或高于术前1~2行;术前平均SE为(+2.63±1.69)D,平均散光值为(-1.45±0.90)D,术后两者均下降,差异有统计学意义(t=5.365,P<0.01;t=-2.359,P<0.05)。远视组术后5眼SE≤±0.50 D,9眼SE≤±1.00 D;术后角膜表面变异指数(ISV)、角膜高度非对称性指数(IHA)及角膜像差系数(ABR)均较术前显著下降,差异有统计学意义(Z=-1.928、-2.135、-1.827,P<0.05)。近视组手术前后UCVA中位数分别为0.92和0.09(logMAR)(Z=-1.863,P<0.05),术后5眼UCVA≤0.3(logMAR),2眼UCVA≤0(logMAR);所有眼BCVA均等于或高于术前1行;术前平均SE为(-3.63±2.26)D,平均散光值为(-1.55±0.70)D,术后两者均显著下降,差异有统计学意义(t=-3.549、-3.143,P<0.05)。近视组术后2眼SE≤±0.50 D,5眼SE≤±1.00 D;术后ISV和IHA较术前显著下降,差异有统计学意义(Z=-1.827、-1.827,P<0.05)。2组术后角膜地形图显示角膜光学区偏小及偏心得到一定程度的改善。术后1年2眼有环形haze,BCVA并未下降。结论 角膜地形图引导LASEK联合MMC治疗RK术后屈光不正合并光学区偏小和(或)偏心安全、有效。  相似文献   

9.
目的探讨核黄素/紫外线A(UVA)诱导的去上皮角膜胶原交联术(CXL)用于青少年圆锥角膜患者的安全性和有效性。方法回顾性自身前后对照研究。选择山东大学附属省立医院2013年10月至2015年10月收治的青少年原发性圆锥角膜患者19例(30眼),予去上皮核黄素/UVA诱导的CXL治疗,术后随访1年,观察术前与术后第3、6、12个月时的裸眼视力(UCVA)、最佳矫正视力(BCVA)、角膜Kmax值、最薄点角膜厚度(TCT)、角膜内皮细胞计数(ECD)等参数变化。采用单组重复测量的方差分析分析术后各时间点与术前各指标的变化情况。结果术前UCVA(LogMAR)为0.78±0.33,术后第3、6、12个月时分别为0.77±0.34、0.72±0.33、0.67±0.31,术后第12个月UCVA与术前比较差异有统计学意义(P<0.001);术前BCVA(LogMAR)为0.42±0.33,术后第3、6、12个月时分别为0.31±0.27、0.29±0.23、0.23±0.20,术后第6、12个月与术前比较差异均有统计学意义(P<0.05);术前及术后各时间点Kmax分别为(62.1±11.3)D、(61.6±9.9)D、(60.4±9.9)D、(59.9±9.5)D,术后第6、12个月与术前比较差异均有统计学意义(P<0.05);TCT由术前的(446±41)μm降低到术后第12个月的(430±39)μm(P<0.001),术后第3、6、12个月时的ECD与术前比较差异均无统计学意义。术中及术后无并发症发生。结论核黄素/UVA诱导的去上皮CXL可以有效提高青少年圆锥角膜患者视力,降低角膜K值且安全性高。  相似文献   

10.
目的:评估经上皮角膜交联(Epi-on CXL)术中采用角膜缘保护技术治疗圆锥角膜的临床应用效果。方法:前瞻性临床研究。选取2019-01/12我院收治拟行Epi-on CXL手术的双眼进展期圆锥角膜患者15例30眼,将右眼15眼纳入试验组,术中采用角膜缘保护技术;左眼15眼纳入对照组,术中不采用角膜缘保护技术。比较两组患眼术前和术后最佳矫正远视力、散光度、角膜曲率Sim-K平均值(Km)、角膜最薄点厚度、泪膜破裂时间及术后不适感、角膜上皮愈合时间的差异。结果:与术前相比,术后3mo时两组最佳矫正远视力、散光度均改善(P<0.05),术后角膜最薄点厚度逐渐减小(P<0.05),术后3mo内泪膜破裂时间变短(P<0.05),但两组之间最佳矫正远视力、散光度、Km、角膜最薄点厚度、泪膜破裂时间、术后不适感方面均无差异(P>0.05),且试验组术后角膜上皮愈合时间比对照组短(3.20±0.56d vs 3.73±0.96d,P=0.041)。结论:角膜缘保护技术能够缩短Epi-on CXL术后角膜上皮愈合时间,初步证实了该技术在Epi-on CXL手术中应用的可行性。  相似文献   

11.
目的:观察角膜胶原交联技术(CXL)的临床应用及治疗效果。方法:回顾性分析郑州市第二人民医院2019年1至6月行CXL或屈光手术联合CXL者62例(84只眼)的临床资料。其中圆锥角膜42例(46只眼),采用核黄素及紫外线诱导的快速去上皮CXL;薄角膜及高度近视20例(38只眼),进行角膜屈光手术联合CXL。术后随访12...  相似文献   

12.
目的:评估离子导入辅助的跨上皮角膜交联治疗青少年圆锥角膜的安全性和有效性。方法:搜集12例(年龄12~18岁,平均15.8±2.08岁)进展期圆锥角膜患者,共15眼,采用0.1%核黄素蒸馏水溶液,离子导入(1 mA电流)辅助跨上皮给药5min,紫外线A(370 nm,3 mW/cm2)照射30min。记录术前、术后3mo和1a的裸眼视力、最佳矫正视力、K1、K2、最大K值、平均K值、角膜散光度数、角膜内皮细胞密度、眼内压、最薄角膜厚度、角膜顶点厚度。角膜参数应用角膜地形图评估,角膜内皮细胞密度应用非接触角膜内皮镜检查。结果:角膜交联1a后,裸眼视力、最佳矫正视力、K1、K2、最大K值、平均K值、角膜散光度数、角膜内皮细胞密度和眼内压均无显著变化。最薄角膜厚度从468.08±33.40μm下降到447.46±40.20μm (t=4.379,P=0.001),差异有统计学意义。角膜顶点厚度从476.07±35.96μm下降到454.60±49.32μm(t=4.270,P=0.001),差异有统计学意义。结论:采用0.1%核黄素蒸馏水溶液的离子导入辅助的角膜交联治疗青少年圆锥角膜是安全、有效的,1 a内能够阻止病情恶化,但是长期效果有待于进一步观察。  相似文献   

13.

Objective

To assess the long-term effects of treatment of progressive keratoconus with ultraviolet A-riboflavin collagen cross-linking (CXL).

Design

This was a prospective clinical study.

Participants

Seventeen eyes of 17 patients with progressive keratoconus were treated with CXL.

Methods

Patients were examined preoperatively, at week 1, months 1, 3, 6, 9, 12, 24, and 36 after treatment. We assessed uncorrected visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA), refraction, biomicroscopy and fundus appearance, intraocular pressure, endothelial cell density (ECD), corneal topography, minimal corneal thickness (MCT), macular optical coherence tomography, axial length, and corneal biomechanics with the ocular response analyzer.

Results

Comparing the 36-month time point results with pretreatment values, we found that UCVA and BSCVA were unchanged. Steepest meridian keratometry (D) and mean cylinder (D) did not show significant change compared with pretreatment values but showed a slight increase as compared with the 24-month time point (53.9 vs 51.7 vs 52.5, and 10.5 vs 8.1 vs 9.2 before, at 24 months, and at 36 months, respectively). Axial length (mm) showed an elongation trend throughout the follow-up period (24.56 vs 24.61 [p = 0.04] vs 24.71 [p = 0.05], before, at 24 months, and at 36 months, respectively). No significant change was observed in ECD, corneal hysteresis and corneal resistance factor, MCT, or foveal thickness.

Conclusions

Three-year results after CXL show stable visual acuity, stable corneal thickness, and stable corneal biomechanical parameters. The decreasing trend in keratometry values that was observed during the first 2 years after CXL was no longer evident. Longer follow-up is needed to decide whether it is a first sign of loss of achieved stability and resumption of keratoconus progression.  相似文献   

14.
目的 观察跨上皮紫外线核黄素角膜胶原交联治疗进展期圆锥角膜的临床效果。方法 前瞻性病例研究。对36例(54眼)的进展期圆锥角膜患者行跨上皮角膜胶原交联手术治疗。表面麻醉下采用意大利SOOFT跨上皮角膜胶原交联仪将0.25%的核黄素导入角膜10 min(电流1.0 mA),370 nm的紫外线照射9 min(能量10 mW/cm2)。平均随诊(14.1±2.3)个月。术后1 d观察角膜上皮愈合情况,术后1、3、6、12个月复诊。检查指标包括UCVA、BCVA、眼压、角膜曲率、角膜厚度、角膜地形图、角膜内皮细胞计数、角膜生物力学、角膜活体激光共聚焦显微镜检查。对手术前后的各项指标行配对t检验。结果 术后1 d裂隙灯显微镜下发现角膜上皮点状混浊、水肿,次日好转。未出现角膜溃疡、角膜溶解、haze、剧烈眼痛等并发症。术后12个月,患者UCVA从4.27±0.23提高到4.41±0.20(t=3.962,P<0.01),BCVA从4.69±0.23提高到4.82±0.14(t=3.507,P<0.01);Kmax下降(1.25±0.68)D(t=9.351,P<0.01);散光值下降(0.30±0.21)D(t=7.227,P<0.01)。角膜最大压陷深度从(1.21±0.11)mm下降为(1.16±0.12)mm(t=4.131,P<0.01)。眼压、角膜内皮细胞密度、角膜厚度治疗前后差异无统计学意义。结论 跨上皮角膜胶原交联法可以有效控制进展期圆锥角膜的发展且未出现类似传统去上皮法导致的多种并发症。跨上皮角膜胶原交联方法是安全、有效的,有望取代去上皮法成为进展期圆锥角膜首选的治疗方式  相似文献   

15.

Background

Corneal scar development after riboflavin-UVA-induced corneal collagen cross-linking (CXL) was retrospectively evaluated.

Patients and methods

A total of 163 CXL-treated eyes in 127 patients with stage 1–3 keratoconus according to Krumeich’s classification were included in this retrospective analysis. The follow-up period was 1 year. At the first and at all follow-up examinations uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), biomicroscopic findings, corneal topography and corneal thickness were recorded.

Results

At 1 year following CXL, 149 eyes (91.4%) of 114 patients had a clear cornea without corneal scar (control group), while 14 eyes (8.6%) of 13 patients developed clinically significant corneal scar (scar group). Preoperatively, the mean K value of the apex was 62.1 ± 13.8 D in the control group and 71.1 ± 13.2 D in the scar group (P=.02). The mean value of corneal thickness before the procedure was 478.1 ± 52.4 μm in the control group and 420.0 ± 33.9 μm in the scar group (P=.001). The UCVA and BCVA, which were preoperatively similar between groups (P=.59, P=.75 respectively), were postoperatively improved in the control group (P=.023, P=.001 respectively), but reduced in the scar group (P=.012, P=.004 respectively).

Conclusion

K-values and corneal thickness could be considered as predictive factors for the possible development of corneal scarring after riboflavin-UVA-induced CXL. Advanced keratoconus appears to be associated with a higher risk of corneal scar development due to lower corneal thickness, greater curvature and intrinsic tissue characteristics.  相似文献   

16.
To evaluate the efficiency and safety of iontophoretic transepithelial corneal crosslinking in pediatric patients with progressive keratoconus underwent general or topical anesthesia in 18 months follow-up. 13 patients (13 eyes) diagnosed with progressive keratoconus underwent corneal CXL with iontophoresis (I-CXL). Riboflavin solution was administered by iontophoresis for 5 min, and then UV-A irradiation (10 mW/cm) was performed for 9 min. Preoperative and post-operative visits at 1, 6, 12, and 18 months assessed the following parameters: uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, corneal topography, optical tomography, and pachymetry with Pentacam (Oculus Optikgeräte GmbH, Wetzlar, Germany), endothelial biomicroscopy (Konan Specular Microscope; Konan Medical, Inc., Hyogo, Japan). The paired Student t test was used to compare data during the follow-up. 10 males and 3 females with a mean age of 15.4 ± 1.7 years (range 11–18 years) were included. The results showed a stabilization of the refractive UCVA and BCVA as early as the first post-operative month, with a slight improvement over time. The Kmax remained stable throughout follow-up (p = 0.04). Transepithelial collagen crosslinking by iontophoresis, unlike other transepithelial techniques seems to halt pediatric keratoconus progression over 18 months. This is the second study evaluating CXL with iontophoresis in pediatric patients with progressive keratoconus with 18 months of follow-up using two different ways of anesthesia.  相似文献   

17.
Purpose: To investigate the correlations between corneal structural modifications assessed by in vivo corneal confocal microscopy with visual function [uncorrected visual acuity (UCVA), best spectacle‐corrected visual acuity (BSCVA)] and morphological data (corneal topography, pachymetry, elevation analysis) after riboflavin UV A corneal collagen cross‐linking (CXL) for the stabilization of progressive keratoconus. Methods: Forty‐four eyes with progressive keratoconus were enrolled in the Siena Eye Cross Study (prospective nonrandomized phase II open trial). All eyes underwent Riboflavin UV A CXL. Preoperative and postoperative evaluation comprised: UCVA, BSCVA, optical pachymetry (Visante OCT, Zeiss, Germany), corneal topography (CSO, Florence, Italy) and tomography (Orbscan IIz; B&L, Rochester, NY, USA) and in vivo confocal microscopy (Heidelberg Retina Tomograph II; Rostock, Heidelberg Gmbh, Germany). Examinations were performed preoperatively 6 months and one day before treatment and at 1, 3, 6 and 12 months of follow‐up. Results: In vivo corneal confocal microscopy showed time‐dependent postoperative epithelial and stromal modifications after cross‐linking. Epithelial thinning associated with stromal oedema and keratocytes apoptosis explained initial tendency towards slightly reduced VA and more glare one month postoperatively in 70% of eyes. Furthermore, a statistically not significant early worsening of topographic mean K values was observed. Orbscan II analysis significantly underestimated pachymetric values after treatment. Pachymetric underestimation was rectified by high‐resolution optical pachymetry provided by the Visante OCT system. After the third post‐CXL month, epithelial thickening, disappearance of oedema and new collagen compaction recorded by in vivo corneal confocal microscopy explained the improvements in visual performance during the follow‐up. Changes in stromal reflectivity and collagen compaction observed by in vivo confocal microscopy were associated with corneal flattening and reduction in anterior elevation values recorded by differential topographic analysis. Conclusion: Corneal structural changes assessed by in vivo corneal confocal microscopy demonstrated significant correlations with visual function (UCVA and BSCVA) and morphological (corneal topography, pachymetry, elevation analysis) findings recorded after riboflavin‐UV A‐induced CXL.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号